Colorectal Cancer Therapeutics Market Size, Share, Analysis & Growth Report: 2015 - 2020 Edition

‘Colorectal Cancer (CRC) Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics’. The report, published by GBI research, is now available for sale on the GBI research website. The study provides exhaustive coverage of the market for colorectal cancer therapeutics in eight developed markets, namely, US, UK, Canada, Germany, France, Italy, Spain, and Japan. The report estimates the size of the colorectal cancer therapeutics market for 2013 and provides forecasts through 2020. The report also covers the epidemiology of the disease, its treatment algorithms and patterns, as well as an analysis of the current pipeline in great detail. The deals landscape of the colorectal cancer therapeutics market is assessed in detail.

Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

According to the findings of the research, the CRC therapeutics market is expected to exhibit a CAGR of 1.8%, to touch US$9.4 billion by the end of 2020. Of all markets studied in this report, the United States was the leader in terms of market share as of 2013. In that year, the US’s share equaled 44.1% of the global market, followed at a distance by Japan (14.7%) and Germany (11.9%). At 4.1%, Spain carried the lowest share among the eight countries included in this report.

Japan will experience the fastest rate of growth—5%—among all other countries through the forecast period, the report states. However, Japan’s marginal growth rate will likely be stymied by aggressively-priced biosimilar versions of cetuximab and bevacizumab. This will occur primarily because the patents of Erbitux and Avastin are inching closer to expiration.

During the forecast period of the report, generic versions of the drug capecitabine are expected to be launched; ultimately impacting the market. However, some of this impact will be mitigated by certain emerging therapies—that are priced at a premium—on the horizon.

The team of analysts that produced this report found that the colorectal cancer therapeutics pipeline is teeming with potential drug candidates scattered across several clinical development phases. With approximately 400 molecules in the active pipeline, a preponderance of these drug candidates being investigated are being assessed for advanced-stage CRC – for both first- and second-line therapies.

Asia-Pacific Colorectal Cancer Therapeutics Market is expected to grow CAGR 6.5% by 2020

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. Explore All Therapeutic Area Market Research Reports at http://www.marketresearchreports.biz/category/37

Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies, which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. 

View Full report at http://www.marketresearchreports.biz/analysis/233908

It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. 

Download Detail Report With COmplete TOC at http://www.marketresearchreports.biz/sample/sample/233909

The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes:

A brief introduction to CRC, including the diseases pathogenesis, etiology, diagnosis and treatment algorithms
In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Browse All Published Reports by GBI Research at http://www.marketresearchreports.biz/publisher/2

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
Accelerate and strengthen your market position by identifying key companies for strategic partnerships

About Us

Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

With a team of experienced consultants we are committed to serve our clients in a way which increase their efficiency, reduce costs and saves time. Our professional search engine helps you in finding the best and latest market research report with just one click of the mouse. Our database represents the most updates and latest market research report collections form all the leading market research publishers across the globe.

Browse Blog at https://businessmonitorinternational.wordpress.com/